JP2024542777A5 - - Google Patents

Info

Publication number
JP2024542777A5
JP2024542777A5 JP2024532973A JP2024532973A JP2024542777A5 JP 2024542777 A5 JP2024542777 A5 JP 2024542777A5 JP 2024532973 A JP2024532973 A JP 2024532973A JP 2024532973 A JP2024532973 A JP 2024532973A JP 2024542777 A5 JP2024542777 A5 JP 2024542777A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
amino acid
acid sequence
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542777A (ja
Filing date
Publication date
Priority claimed from PCT/EP2021/086689 external-priority patent/WO2022136209A1/en
Application filed filed Critical
Priority claimed from PCT/EP2022/084075 external-priority patent/WO2023099668A1/en
Publication of JP2024542777A publication Critical patent/JP2024542777A/ja
Publication of JP2024542777A5 publication Critical patent/JP2024542777A5/ja
Pending legal-status Critical Current

Links

JP2024532973A 2021-12-03 2022-12-01 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎(crswnp)又は鼻ポリープを伴わない慢性副鼻腔炎(crssnp)の処置における使用のためのインターロイキン5結合タンパク質投与レジメン Pending JP2024542777A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163285513P 2021-12-03 2021-12-03
US63/285,513 2021-12-03
PCT/EP2021/086689 WO2022136209A1 (en) 2020-12-22 2021-12-20 Interleukin 5 binding protein dosage regimen
EPPCT/EP2021/086689 2021-12-20
US202263349622P 2022-06-07 2022-06-07
US63/349,622 2022-06-07
PCT/EP2022/084075 WO2023099668A1 (en) 2021-12-03 2022-12-01 Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)

Publications (2)

Publication Number Publication Date
JP2024542777A JP2024542777A (ja) 2024-11-15
JP2024542777A5 true JP2024542777A5 (cg-RX-API-DMAC7.html) 2025-12-08

Family

ID=84688427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532973A Pending JP2024542777A (ja) 2021-12-03 2022-12-01 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎(crswnp)又は鼻ポリープを伴わない慢性副鼻腔炎(crssnp)の処置における使用のためのインターロイキン5結合タンパク質投与レジメン

Country Status (5)

Country Link
US (1) US20250042985A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440617A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542777A (cg-RX-API-DMAC7.html)
CA (1) CA3239667A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023099668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026047072A1 (en) * 2024-08-30 2026-03-05 Glaxosmithkline Intellectual Property Development Limited Medical use
WO2026078117A1 (en) * 2024-10-11 2026-04-16 Glaxosmithkline Intellectual Property Development Limited Anti-il-5 antibody in the treatment of chronic rhinosinusitis with nasal polyps

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202600240T1 (it) 2017-05-26 2026-07-16 Glaxosmithkline Ip Dev Ltd Composizioni biofarmaceutiche e metodi correlati
WO2019224724A1 (en) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising antibody variants

Similar Documents

Publication Publication Date Title
JP2025169389A5 (cg-RX-API-DMAC7.html)
RU2006120950A (ru) Антитело к cd40: препарат и способы
JP2022532927A5 (cg-RX-API-DMAC7.html)
KR20060123483A (ko) 허혈성 병변의 치료 및 예방을 위한 트레프로스티닐의 용도
JP2019521156A5 (cg-RX-API-DMAC7.html)
JP2021532176A5 (cg-RX-API-DMAC7.html)
JP2022518944A5 (cg-RX-API-DMAC7.html)
JP2024539148A5 (cg-RX-API-DMAC7.html)
WO2011097148A3 (en) Use of oral heparin preparations to treat urinary tract diseases and conditions
JP2024543885A5 (cg-RX-API-DMAC7.html)
JP2024531314A (ja) 小児msを治療するためのオファツムマブ
JP2024500912A5 (cg-RX-API-DMAC7.html)
JP2022514561A5 (cg-RX-API-DMAC7.html)
CN114588164B (zh) 瑞马唑仑在预防围术期低体温和寒战中的应用
JP2021523096A5 (cg-RX-API-DMAC7.html)
AU2017223970B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
KR100302994B1 (ko) 약독화된비면역원성폭스바이러스또는파라폭스바이러스로부터멀티포텐트파라폭스면역유발인자의약제로서이용하는새로운적용
JP2022543956A (ja) 安定なアルブビルチド組成物
IL312401A (en) Methods for treating Crohn's disease with a specific anti-IL23 antibody
IL316022A (en) Method of treating mild to moderate psoriasis with il-23 specific antibody
JP2022526493A5 (cg-RX-API-DMAC7.html)
IL297217A (en) pan-elr antibodies and chemokine cxc for the treatment of respiratory diseases
CN108014337B (zh) 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物
US20230277650A1 (en) Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv)
RU2180532C2 (ru) Способ лечения папилломатоза